Competitive advantages by "Choice and Concentration Strategy" tailored to the corporate development stages
Unlike other conventional biotech companies, DuChemBio has achieved a consolidated growth based on solid sales.
After securing cutting-edge manufacturing facilities and competent human resources,
DuChemBio has completed its own peculiar business scheme. It is expected to realize high profit from 2022.
※ Launching schedules for new drugs
FACBCFirst half of 2022
FESSecond half of 2022
68Ga-PSMA-11First half of 2023
Contact email@example.com to get more information